NASDAQ$PRAX
Praxis Precision Medicines I · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Praxis Precision Medicines reported financial results and provided a corporate update.
Praxis Precision Medicines reported a net loss of $51.9 million for Q3 2024, with research and development expenses increasing to $41.9 million. The company's cash, cash equivalents, and marketable securities totaled $411.2 million as of September 30, 2024, providing a runway into 2027. Key clinical programs, including ulixacaltamide, vormatrigine, and relutrigine, are advancing towards registrational readiness.
- Advanced relutrigine into late-stage development, marking a third molecule with blockbuster potential.
- Finalized the operational plan to complete the interim analysis for Essential3 Study 1 for ulixacaltamide in mid-Q1 2025.
- Progressed the SCN2A/8A program to registrational stage and expanding studies to cover a broader range of DEEs based on positive EMBOLD cohort 1 results.
- The EMPOWER observational study started enrolling patients in the third quarter of 2024 and has already enrolled over 1,000 patients.
Headline financials
Revenue & EPS history
Praxis · Revenue · Quarterly
$302K
Revenue by segment
Praxis · $500K total across 1 segment · Q3 2023
- Collaboration Revenue$500K—100.0%
Forward guidance
Praxis Precision Medicines is set to build on its momentum, advancing all four clinical programs towards registrational readiness in 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
-0.3%
Avg return
Earnings day
+3.3%
Avg return
5 days after
-4.0%
Avg return
30 days after
57%
13 / 23 earnings
Positive
+22.3%
Q2 2022
Best reaction
-40.6%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.7% | -6.4% | -22.2% | |
| Q4 2025 | +0.5% | +4.2% | -9.3% | |
| Q3 2025 | -4.7% | -2.2% | +44.4% | |
| Q1 2025 | +0.2% | -3.5% | +16.3% | |
| Q4 2024 | -40.6% | -41.8% | -40.6% | |
| Q3 2024 | +3.6% | +16.6% | -4.0% | |
| Q2 2024 | -1.1% | +2.0% | +13.3% | |
| Q1 2024 | -5.9% | -6.9% | -15.8% | |
| Q4 2023 | +6.3% | +2.3% | -7.3% | |
| Q3 2023 | +1.4% | -0.6% | +21.6% | |
| Q2 2023 | +10.8% | +17.0% | +43.9% | |
| Q1 2023 | -2.8% | -1.9% | -7.7% | |
| Q4 2022 | -4.2% | -13.0% | -77.0% | |
| Q3 2022 | -12.5% | -11.2% | -13.3% | |
| Q2 2022 | +22.3% | +33.2% | -3.4% | |
| Q1 2022 | +14.0% | +28.1% | -77.7% | |
| Q4 2021 | -1.9% | -4.2% | -22.9% | |
| Q3 2021 | +2.4% | +2.0% | -17.1% | |
| Q2 2020 | +12.7% | +35.9% | +42.8% | |
| Q2 2021 | +12.7% | +35.9% | +42.8% | |
| Q1 2021 | -16.4% | -16.1% | -20.2% | |
| Q4 2020 | -6.8% | -11.5% | -34.0% | |
| Q3 2020 | +2.3% | +18.2% | +54.7% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro